Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Cost Avoidance and Clinical Pharmacist Interventions on Hospitalized Patients in Hematologic malignancies

혈액종양 입원 환자 대상 임상약사의 처방중재활동 및 회피비용 분석

  • Kim, Ye Seul (Department of Pharmacy, Seoul National University Bundang Hospital) ;
  • Hong, So Yeon (Department of Pharmacy, Seoul National University Bundang Hospital) ;
  • Kim, Yoon Hee (Department of Pharmacy, Seoul National University Bundang Hospital) ;
  • Choi, Kyung Suk (Department of Pharmacy, Seoul National University Bundang Hospital) ;
  • Lee, Jeong Hwa (Department of Pharmacy, Seoul National University Bundang Hospital) ;
  • Lee, Ju-Yeun (College of Pharmacy & Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Lee, Euni (College of Pharmacy & Research Institute of Pharmaceutical Sciences, Seoul National University)
  • 김예슬 (분당서울대학교병원 약제부) ;
  • 홍소연 (분당서울대학교병원 약제부) ;
  • 김윤희 (분당서울대학교병원 약제부) ;
  • 최경숙 (분당서울대학교병원 약제부) ;
  • 이정화 (분당서울대학교병원 약제부) ;
  • 이주연 (서울대학교 약학대학) ;
  • 김은경 (서울대학교 약학대학)
  • Received : 2022.08.10
  • Accepted : 2022.09.19
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Patients with hematologic cancers have a risk of drug-related problems (DRPs) from medications associated with chemotherapy and supportive care. Although the role of oncology pharmacists has been widely documented in the literature, few studies have reported its impact on cost reduction. This study aimed to describe the activities of oncology pharmacists with respect to hematologic diseases and evaluate the associated cost avoidance. Methods: From January to July 2021, patients admitted to the department of hemato-oncology at Seoul National University, Bundang Hospital were studied. The activities of oncology pharmacists were reported by DRP type following the Pharmaceutical Care Network version 9.1 guidelines, and the acceptance rate was calculated. The avoided cost was estimated based on the cost of the pharmacy intervention, pharmacist manpower, and prescriptions associated with the intervention. Results: Pharmacists intervened in 584 prescriptions from 208 patients during the study period. The most prevalent DRP was "adverse drug event (possibly) occurring" (32.4%), followed by "effect of drug treatment not optimal" (28.6%). "Drug selection" (42.5%) and "dose selection" (30.3%) were the most common causes of DRPs. The acceptance rate of the interventions was 97.1%. The total avoidance cost was KRW 149,468,321; the net profit of the avoidance cost, excluding labor costs, was KRW 121,051,690; and the estimated cost saving was KRW 37,223,748. Conclusion: Oncology pharmacists identified and resolved various types of DRPs from prescriptions for patients with hematologic disease, by reviewing the prescriptions. Their clinical service contributed to enhanced patient safety and the avoidance of associated costs.

Keywords

References

  1. Lee JJ, Ahn JS. Recently increasing hematologic diseases in Korea. Korean J Med 2010;78(5):557-63.
  2. Serrano-Fabia A, Albert-Mari A, Almenar-Cubells D, JimenezTorres NV. Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy. J Oncol Pharm Pract 2010;16(2):105-12. https://doi.org/10.1177/1078155209340482
  3. Prot-Labarthe S, Therrien R, Demanche C, Larocque D, Bussieres JF. Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service. J Oncol Pharm Pract 2008;14(3):147-52. https://doi.org/10.1177/1078155208093929
  4. Dormann, H., Muth-Selbach, U., Krebs, S. et al. Incidence and Costs of Adverse Drug Reactions During Hospitalisation. Drug Safety. 2000;22(2)161-8. https://doi.org/10.2165/00002018-200022020-00007
  5. Lee EJ, Polypharmacy and inappropriate medications in older adults. In: The Korean Association Of Internal Medicine autumn conference, Seoul, Korea, October 25, 2013.
  6. Cho YS, Ahn JS. Management of adverse drug events with polypharmacy in older patients. JKSHP 2011;28(3):219-221.
  7. Leger DY, Moreau S, Signol N, et al. Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: observational single-center study of 122 patients. J Geriatr Oncol 2018;9(1):60-7. https://doi.org/10.1016/j.jgo.2017.07.015
  8. Balk TE, van der Sijs IH, van Gelder T, et al. Drug-drug interactions in pediatric oncology patients. Pediatr Blood Cancer 2017;64(7);e26410. https://doi.org/10.1002/pbc.26410
  9. Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res 2015;35(1):457-60.
  10. Chen PZ, Wu CC, Huang CF. Clinical and economic impact of clinical pharmacist intervention in a hematology unit. J Oncol Pharm Pract 2020;26(4):866-72. https://doi.org/10.1177/1078155219875806
  11. Jeong CR. Analysis of drug-related problems (DRPs) and evaluation of the value of clinical pharmacists interventions for patients with hematologic malignancies. M.S. Thesis for Pharmacy Seoul National University. 2014.
  12. Yoo JS, Lee SY, Kim JS, Son ES, Yu YM. Evaluation of clinical pharmacist's interventions in hematology. J Kor Soc Health-syst Pharm 2020;37(4):429-43.
  13. Pharmaceutical Care Network Europe Association. PCNE classification for drug-related problems. Available from https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf. Accessed June 21, 2021.
  14. WHOCC. ATC/DDD Index 2022. Available from https://www.whocc.no/atc_ddd_index/. Accessed January 15, 2022.
  15. Park BG, Baek A, Kim YH, et al. Clinical and economic impact of medication reconciliation by designated ward pharmacists in a hospitalist-managed acute medical unit. Res Social Adm Pharm 2022;18(4):2683-90. https://doi.org/10.1016/j.sapharm.2021.06.005
  16. Eichenberger PM, Lampert ML, Kahmann IV, van Mil JF, Hersberger KE. Classification of drug-related problems with new prescriptions using a modified PCNE classification system. Pharm World Sci 2010;32(3):362-72. https://doi.org/10.1007/s11096-010-9377-x
  17. Jamal I, Amin F, Jamal A, Saeed A. Pharmacist's interventions in reducing the incidences of drug related problems in any practice setting. International current pharmaceutical journal 2015;4(2):347-52. https://doi.org/10.3329/icpj.v4i2.21483
  18. Nielsen TRH, Andersen SE, Rasmussen M, Honore PH. Clinical pharmacist service in the acute ward. Int J Clin Pharm 2013;35(6):1137-51. https://doi.org/10.1007/s11096-013-9837-1
  19. van Mil JF, Westerlund LT, Hersberger KE, Schaefer MA. Drugrelated problem classification systems. Ann Pharmacother 2004;38(5):859-67. https://doi.org/10.1345/aph.1D182
  20. Kim KS, Suh SY, Lim JM, Lee J, Koh Y, and Suh HS, Assessment of economic benefit of clinical pharmacy services in oncology. Yakhak Hoeji 2020;64(3):219-25. https://doi.org/10.17480/psk.2020.64.3.219
  21. Koo HK. Effects of adverse drug reactions detected using monitoring program on the length of stay and charges in the hospital setting (doctoral dissertation). Ph.D. Thesis for Medicine Seoul National University. 2009.
  22. The Korean Society of Health-System Pharmacists. Survey results of hospital pharmacy. In: Hospital pharmacy leadership education series, Korea, September 30, 2021.
  23. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 2018;36(30):3043-54. https://doi.org/10.1200/JCO.18.00374
  24. Ministry of Food and Drug Safety. Mabthera®. Available from https://nedrug.mfds.go.kr/searchDrug. Accessed July 5, 2022.
  25. Ministry of Food and Drug Safety. Darzalex®. Available from https://nedrug.mfds.go.kr/searchDrug. Accessed July 5, 2022.
  26. Oliveira CS, Silva MP, Miranda IK, Calumby RT, de Araujo-Calumby RF. Impact of clinical pharmacy in oncology and hematology centers: A systematic review. J Oncol Pharm Pract 2021;27(3):679-92. https://doi.org/10.1177/1078155220976801
  27. Moukafih B, Abahssain H, Mrabti H, et al. Impact of clinical pharmacy services in a hematology/oncology ward in Morocco. J Oncol Pharm Pract 2021;27(2):305-11. https://doi.org/10.1177/1078155220919169
  28. Lee SY, Cho E. A systematic review of outcomes research in the hospital pharmacists' interventions in south korea. Korean J Clin Pharm 2019;29(3):193-201. https://doi.org/10.24304/kjcp.2019.29.3.193
  29. Kim HT, Kwon MS, Oh HJ, Suh HS. Clinical and economic effects of pharmaceutical care: A systematic review. Journal of Korean Academy of Social & Managed Care Pharmacy 2019;7(1):39-51.
  30. Waddell JA, Solimando Jr DA, Strickland WR, Smith BD, Wray MK. Pharmacy staff interventions in a medical center hematologyoncology service. J Am Pharm Assoc (Wash) 1998;38(4):451-6. https://doi.org/10.1016/S1086-5802(16)30346-1
  31. Wu HT, Graff LR, Yuen CW. Clinical pharmacy in an inpatient leukemia and bone marrow transplant service. Am J Health Syst Pharm 2005;62(7):744-7. https://doi.org/10.1093/ajhp/62.7.744
  32. Han JM, Ah YM, Suh SY, et al. Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm 2017;38(5):1124-32.